title: Topical mitomycin C for the treatment of conjunctival tumor.
abstract: BACKGROUND
  To evaluate the efficacy of topical mitomycin C (MMC) for the treatment of conjunctival tumor in a prospective design.
  
  
  METHODS
  Nine patients (nine eyes) with conjunctival tumor were studied. The patients received topical MMC 0.04% four times daily by one to six courses. Each course consisted of medication for consecutive 7 days followed by 1 week without medication. Follow-up was conducted on patients for control of disease, and side effects.
  
  
  RESULTS
  In 7 patients, the tumor completely disappeared during the mean follow-up period of 24.57 +/- 5.94 months (range 18-35 months) with no recurrence. In 1 patient, there was no regression of the tumor, and in 1 patient cessation of the treatment was needed because of an adverse effect of the drug.
  
  
  CONCLUSIONS
  Topical MMC is effective for the treatment of conjunctival tumor. Longer follow-up and large series are needed to assess the duration of tumor control.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Cukurova University, Adana, Turkey. altanoz@cu.edu.tr
authors.forename: Altan Atakan
authors.initials: AA
authors.lastname: Ozcan
authors.forename: Selcuk
authors.initials: S
authors.lastname: Sizmaz
authors.forename: Meltem
authors.initials: M
authors.lastname: Yagmur
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000188:drug therapy*; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009883:Ophthalmic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000903:Antibiotics, Antineoplastic; D009883:Ophthalmic Solutions; D016685:Mitomycin